← Back to Search

Contrast Agent

Iso-Osmolar Contrast Media for Coronary Artery Disease (GE OCT Trial)

Phase 4
Waitlist Available
Led By Emmanouil Brilakis, MD, PhD
Research Sponsored by Minneapolis Heart Institute Foundation
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up during and 30 seconds after injection
Awards & highlights

GE OCT Trial Summary

This trial will compare the effects of two different types of contrast agents on OCT images and heart function.

Eligible Conditions
  • Coronary Artery Disease
  • Contrast Media Reaction

GE OCT Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~30 seconds after injection
This trial's timeline: 3 weeks for screening, Varies for treatment, and 30 seconds after injection for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Contrast Volume after Injection
Secondary outcome measures
Clear OCT Images
Electrocardiographic (ECG) Changes

GE OCT Trial Design

2Treatment groups
Active Control
Group I: Iso-Osmolar Contrast MediaActive Control2 Interventions
Will receive iso-osmolar media first, low-osmolar media second
Group II: Low-Osmolar Contrast MediaActive Control2 Interventions
Will receive low-osmolar media first, iso-osmolar media second

Find a Location

Who is running the clinical trial?

Minneapolis Heart Institute FoundationLead Sponsor
29 Previous Clinical Trials
15,403 Total Patients Enrolled
7 Trials studying Coronary Artery Disease
10,341 Patients Enrolled for Coronary Artery Disease
Emmanouil Brilakis, MD, PhDPrincipal InvestigatorMinneapolis Heart Institute
2 Previous Clinical Trials
3,296 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there still openings for participants in this clinical research project?

"Affirmative. The information hosted on clinicaltrials.gov indicates that this trial is actively in search of applicants, having been posted on the 30th September 2021 and most recently updated a few weeks ago on October 19th, 2021. 62 candidates need to be enrolled from 1 location."

Answered by AI

What medical applications is Low-Osmolar Contrast Media typically employed for?

"Low-Osmolar Contrast Media is frequently used for abdominal ct in addition to contrast enhanced computed tomography (ct) scanning, contrast enhancement, and peripheral venography."

Answered by AI

How many individuals are actively engaging in this research program?

"That is accurate. Per the information on clinicaltrials.gov, this research study commenced recruitment on 30th September 2021 and was last modified 19th October 2021. It requires 62 volunteers at a single location to take part."

Answered by AI

What prior research exists on the safety and efficacy of Low-Osmolar Contrast Media?

"At the present moment, 10 Low-Osmolar Contrast Media clinical trials are in progress and none have reached phase 3. Despite this, 173 locations throughout the US offer testing for these media with many of them located near Joplin, Missouri."

Answered by AI

How deleterious are the effects of Low-Osmolar Contrast Media for individuals?

"We have rated Low-Osmolar Contrast Media's safety a 3, as this is an approved Phase 4 trial."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
Iso-Osmolar vs. Low-Osmolar Contrast Agents for Optical Coherence Tomography
2021. "Iso-Osmolar vs. Low-Osmolar Contrast Agents for Optical Coherence Tomography". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05065073.
~18 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top